

Healthy Volunteers

## Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03236844 WP40052

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administration.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03236844 WP40052**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years & <= 80 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---